Novartis Deutschland

Novartis is a registered trademark of Novartis AG. Investments span every aspect of our business: from research and development, to manufacturing and supply chain, through commercial, medical, and patient care. Enterprise software & services that improve the commercialization of pharma and healthcare products. Investing in novel but overlapping products, features, business models. Investing in novel but overlapping products, features, business models.

We are committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a commitment to advancing patient care through transdermal drug delivery. Noven’s Mission: To develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven's history began in 1987 in Miami, Florida, with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to benefit patients across a range of therapeutic conditions. Today, Noven is the US platform for Hisamitsu, the world's largest patch manufacturer, with fully integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and mental health. We are a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., the world’s largest manufacturer of transdermal patches. Please be advised that Noven has no control over the content or presentation of the site you are about to view. To return to Noven.com, click "Cancel" or close this window. Noven is committed to developing and offering products and technologies that meaningfully benefit patients.

Learn about our 113-year history and join us on our new exciting journey. Read about our established portfolio and new treatment options. We have more than a 100-year of experience with drug development and discovery. Learn more about our available job opportunities and work culture. 7 Giralda Farms - 2nd Floor Madison, NJ 07940 USA.

We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. We are making great progress on our strategic goals. We are a science-led company at our core. We are also one of the most-admired companies to work for in the pharmaceutical and biotechnology sector. We are committed to maintaining complete transparency about all aspects of our business. We are committed to improving the quality of life through affordable medicines. We are a team of over 6000 talented and energetic individuals who strive to widen the frontiers of chemistry in order to help develop new cures, while building a profitable business. Continuous innovation is the lifeblood of our business.

For novisgroup, changing market conditions are exciting opportunities for the success of our partners and our teams. Since its foundation, novis has developed into a competent general agent and service provider for consumer products. An experienced staff makes novis your competent partner. We are always there for you, because personal customer service plays a very important role for us. We are on site, because no distance is too far for us. We are the interface to various departments as well as internal and external customers - always friendly and competent in German, French, English and Italian. That's the reason why novis finds the ideal route for innovative products from the factory to the consumer. As a novis customer, you benefit from numerous opportunities that enable you to discover new chances and paths in our industry.

Founding of NUVISAN ICB GmbH and takeover from Bayer of a fully equipped pharmaceutical research unit with 400 workplaces in the field of small-molecule active ingredients. NUVISAN expands its portfolio to phase II patient trials by acquiring the CRO INAMED in Gauting, near Munich (Germany). NUVISAN acquires from NESTLÉ SKIN HEALTH parts of the Galderma research activities at Sophia Antipolis (France). Founding of NUVISAN Inc., a subsidiary of NUVISAN GmbH, in Boston, Massachusetts (USA). Founding as NUVISAN GmbH after the sale of the AAIPharma group of companies to new owners. NUVISAN The Science CRO has received a $9.6 million grant from the Bill & Melinda Gates Foundation for breakthrough discovery and early development of new non-hormonal contraceptives. NUVISAN ICB was awarded the 2023 EcoVadis Gold Medal for Sustainability, which highlights our commitment to reducing our carbon footprint and making a positive impact on the community. Explore NUVISAN's scientific publications, videos, webinars, and more to gain insights into our solutions and projects, and see how our teams can support your scientific journey.